Nevisense – AI powered technology for more accurate melanoma detection

Nevisense is the world’s first objective diagnostic support tool for non-visual detection of malignant melanoma. By gathering and analyzing precise electrical measurements in the epidermis and dermis, it provides reliable information unavailable through any other method. Nevisense enables you to objectively analyze imdeterminate pigmented skin lesions.

The diagnostic challenge

Most dermatologists feel confident with today’s methods of visual examination. Literature shows, however, that the accuracy of clinical diagnosis of cutaneous melanoma with or without dermoscopy is far from 100%.
The consequences of this uncertainty are two-fold. On the one hand, life-threatening melanoma may be missed. On the other, as a safety precaution, benign lesions are unnecessarily excised. Nevisense provides additional information valuable in the process to detect melanoma.

The Nevisense solution

With Nevisense, SciBase has developed an innovative method for improving accuracy in the detection of malignant melanoma. Utilizing Electrical Impedance Spectroscopy (EIS), applied as a harmless electrical signal to the skin, Nevisense provides a reliable, objective and non-invasive analysis of atypical skin lesions that complements the providers regular clinical evaluations.

The Nevisense method is safe. By providing valuable diagnostic information that is unavailable through other methods, it allows physicians to make more informed biopsy management decisions when analyzing atypical pigmented skin lesions. Nevisense, used as a diagnostic support tool, makes it possible to increase diagnostic accuracy.